Oxidative stress and vascular function: Implications for pharmacologic treatments

Current Hypertension Reports

Volumn 12, Issue 3, 2010, Pages 154-161

  Weseler, Antje R ^a   Bast, Aalt ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antihypertensive drugs; Antioxidant; ENOS; Flavonoids; Hypertension; NADPH oxidase; NO; NOX; Oxidative stress; Oxygen radicals; Polyphenols; Reactive oxygen species; ROS; Vasculature; Xanthine oxidase

Indexed keywords

21 AMINOSTEROID; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTIOXIDANT; APOCYNIN; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CARDIOVASCULAR AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLAVONOID; FLAVONOID 7 MONOHYDROXYETHYLRUTOSIDE; LOSARTAN; NIFEDIPINE; NISOLDIPINE; POLYPHENOL DERIVATIVE; PR 39; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAS 2870; XANTHINE OXIDASE;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CELL PROLIFERATION; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE;

ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FLAVONOIDS; FREE RADICALS; HUMANS; HYPERTENSION; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHENOLS; REACTIVE OXYGEN SPECIES; XANTHINE OXIDASE;

EID: 77956395196     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0103-9     Document Type: Review

References (47)

1. Poli G, Leonarduzzi G, Biasi F, Chiarpotto E: Oxidative stress and cell signalling. Curr Med Chem 2004, 11:1163-1182.
2. Ushio-Fukai M: Vascular signaling through G protein-coupled receptors: new concepts. Curr Opin Nephrol Hypertens 2009, 18:153-159, This is a comprehensive review of the role of ROS in G protein-coupled receptor signaling.
3. Bedard K, Krause K: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245-313, This excellent review provides detailed information about the role of NOX in health and disease.
4. Cave AC, Brewer AC, Narayanapanicker A, et al.: NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 2006, 8:691-728.
5. Guzik TJ, Harrison DG: Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Disc Today 2006, 11:524-533, This very interesting article discusses new approaches for inhibiting NADPH oxidases. The authors make it clear that besides direct ROS scavenging, an indirect antioxidant action also is a strategy for modulating vascular oxidative stress.
6. Nauseef WM: Biological role for the NOX family NADPH oxidases. J Biol Chem 2008, 283:16961-16965.
7. Ushio-Fukai M: Compartmentalization of redox signaling through NADPH-oxidase-derived RO.S. Antioxid Redox Signal 2009, 11:1289-1299.
8. Nishino T, Okamoto K, Eger BT, et al.: Mammalian xanthine oxidoreductase-mechanisms of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J 2008, 275:3278-3289.
9. Berry CE, Hare JM: Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 2004, 555:589-606.
10. Harrison R: Structure and function of xanthine oxidoreductase: where are we now? Free Rad Biol Med 2002, 33:774-797.
11. Radi R, Rubbo H, Bush K, Freeman BA: Xanthine oxidase binding to glucosaminoglycans: kinetics and superoxide dismutase interactions of immobilized xanthine oxidase-heparin complexes. Arch Biochem Biophys 1997, 339:125-135.
12. Landmesser U, Spiekermann S, Dikalov S, et al.: Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002, 106:3073-3078.
13. Ungvari Z, Gupte SA, Recchia FA, et al.: Role of oxidativenitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 2005, 3:221-229.
14. Förstermann U: Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem 2006, 387:1521-1533.
15. Higashi Y, Sasaki S, Nakagawa K, et al.: Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens 2002, 15:326-332.
16. Stroes E, Kastelein J, Cosentino F, et al.: Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997, 99:41-46.
17. Heitzer T, Brockhoff C, Mayer B, et al.: Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res 2000, 86:E36-E41.
18. Moncada S, Higgs EA: Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995, 9:1319-1330.
19. Holowatz LA, Kenney WL: Up-regulation of arginase activity contributes to attenuated reflex cutaneous vasodilation in hypertensive humans. J Physiol 2007, 581:863-872.
20. Sydow K, Munzel T: ADMA and oxidative stress. Atheroscl Suppl 2003, 4:41-51.
21. Rekka E, Mannhold RM, Bast A, et al.: Molecular pharmacological aspects of antiarrhythmic activity I. Class I and class III compounds and lipid peroxidation. Biochem Pharmacol 1990, 39:95-100.
22. Yue T-L, Cheng H-Y, Lysko PG, et al.: Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol Exp Ther 1992, 263:92-98.
23. Dulin B, Abraham WT: Pharmacology of carvedilol. Am J Cardiol 2004, 93:3B-6.B.
24. Jonsson G, Abdelnoor M, Seljeflot I, et al.: The antioxidant effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. J Cardiovasc Pharmacol 2007, 49:27-32.
25. Kauder WF, Watts JA: Antioxidant properties of dihydropyridines in isolated rat hearts. Biochem Pharmacol 1996, 51: 811-819.
26. 2+ channel blockers (nifedipine, diltiazem and verapamil) against the toxicity of oxidized low density lipoprotein to cultured lymphoid cells. Br J Pharmacol 1992, 107:738-744.
27. Bartosz M, Kedziora J, Bartosz G: Antioxidant and prooxidant properties of captopril and enalapril. Free Rad Biol Med 1997, 23:729-735.
28. de Cavanagh EM, Inserra F, Ferder L, et al.: Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissue. Am J Physiol Regul Integr Comp Physiol 2000, 278:R572-R577.
29. Lapenna D, De Gioia S, Ciofani G, et al.: Captopril has no significant scavenging antioxidant activity in human plasma in vitro or in vivo. Br J Clin Pharmacol 1996, 42:451-456.
30. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994, 74:1141-1148.
31. van der Giet M, Erinola M, Zidek W, et al.: Captopril and quinapril reduce reactive oxygen species. Eur J Clin Invest 2002, 32:732-737.
32. Adam O, Laufs U: Antioxidative effects of statins. Arch Toxicol 2008, 82:885-892.
33. George J, Struthers AD: Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag 2009, 5:265-272, This article discusses the role of XO in vascular oxidative stress. The research on allopurinol as an inhibitor of XO and its encouraging effect on endothelial dysfunction are reported.
34. Hall ED: Efficacy and mechanisms of action of the cytoprotective lipid peroxidation inhibitor tirilazad mesylate in subarachnoid haemorrhage. Eur J Anaesthesiol 1996, 13:279-289.
35. Petty MA, Grisar JM, de Jong W: Protective effects of an alphatocopherol analogue against myocardial reperfusion injury in rats. Eur J Pharmacol 1992, 210:85-90.
36. Garcia G, Rodriguez-Puyol M, Alajarin R, et al.: Losartanantioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage. J Med Chem 2009, 52:7229-7227, This article provides a nice example of the medical-chemical approach to designing chimeric molecules that combine an established cardiovascular pharmacologic effect with an antioxidant action.
37. Koini EN, Papazafiri P, Vassilopoulos A, et al.: 5,7,8- Trimethylbenzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury. J Med Chem 2009, 52:2328-2340.
38. Hamblin M, Chang L, Zhang J, et al.: The role of peroxisome proliferator-activated receptor gamma in blood pressure regulation. Curr Hypertens Rep 2009, 11:239-245.
39. Bast A, Haenen GR, Bruynzeel AM, et al.: Protection by flavonoids against anthracycline cardiotoxity: from chemistry to clinical trials. Cardiovasc Tox 2007, 7:154-159.
40. de Celle T, Heeringa P, Strzelecka AE, et al.: Sustained protective effects of 7-monohydroxyethylrutoside in an in vivo model of cardiac ischemia-reperfusion. Eur J Pharmacol 2004, 494:205-212.
41. Weseler AR, Geraets L, Moonen HJJ, et al.: Poly(ADP-ribose) polymerase-1-inhibiting flavonoids attenuate cytokine release in blood from male patients with chronic obstructive pulmonary disease or type 2 diabetes. J Nutr 2009, 139:952-957.
42. John JH, Ziebland S, Yudkin P, et al.: Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure; a randomized controlled trial. Lancet 2002, 359:1969-1974.
43. Caton PW, Pothecary MR, Lees DM, et al.: Regulation of vascular endothelial function by procyanidin-rich foods and beverages. J Agric Food Chem 2010 Jan 28 (Epub ahead of print).
44. Schnorr O, Brossette T, Momma TY, et al.: Cocoa flavanols lower vascular arginase activity in human endothelial cells in vitro and in erythrocytes in vivo. Arch Biochem Biophys 2008, 476:211-215.
45. Schewe T, Steffen Y, Sies H, et al.: How do flavanols improve vascular function? A position paper. Arch Biochem Biophys 2008, 476:102-106.
46. de Leeuw PW, Bast A: Tomato extract for hypertension? Cardiovasc Drugs Ther 2009, 23:107-108.
47. Steffen Y, Gruber C, Schewe T, et al.: Mono-O-methylated flavanols and other flavonoids as inhibitors of endothelial NADPH oxidase. Arch Biochem Biophys 2008, 469:209-219.